Self-Audit Series #13: Diabetic Test Strips
The 2020 National Diabetes Statistics Report, analyzed data through 2018 and found that there are over 34 million Americans with diabetes (approximately 1 in 10 Americans). Additionally, there are 88 million Americans with prediabetes (approximately 1 in 4 Americans). Based off this data, there are more than 120 million people in the United States that are living with diabetes or prediabetes. Due to the high volume of claims for diabetic test strips, they continue to receive significant attention during third-party audits. Follow the tips below to be prepared if you get an audit.
Purchasing Requirements
- PBM contracts require that pharmacies purchase test strips from vendors that are licensed distributors in your state
- OptumRx® requires purchases from suppliers that have received NABP’s Drug Distributor Accreditation (DDA) (formerly known as “VAWD® Accreditation”)
- Caremark® and Express Scripts® also require test strips to be purchased directly from the manufacturer or from authorized distributors only.
- Consider purchasing test strips from one approved wholesaler to make things easier
- Major test strip manufacturer’s have lists of “authorized distributers” on their websites
- Beware of secondary wholesalers which are subsidiaries of authorized distributors who may not show up on the authorized list (e.g., River City and Masters)
Billing
- Make sure that prescriptions have calculable instructions – use as directed is not accepted upon an audit
- Confirm that you are billing the correct NDC – many test strips have a “retail” version and a “Medicare/Medicaid only” version
- Verify the NDC billed is for the correct package size – do not bill the #100 count NDC if you are dispensing the #50 count box
- Dispense only one NDC per claim – you should not dispense 1 x #100 count and 1 x #50 count to equal #150 test strips
- Dispense the package size that is closest to the total quantity – if the prescription is for #200, dispense 2 x #100 count, not 4 x #50 count; some plans prohibit dispensing smaller packages
- Submit the accurate days’ supply based on the quantity and instructions
- If you are billing DMEPOS for Medicare beneficiaries, make sure that you submit the correct modifier to indicate if the patient is using insulin (KX) or not using insulin (KS)
- Some payers may require a diagnosis code at the time of billing to support the clinical need
Additional Newsline Article References for Self-Audit
- If you are delivering or mailing test strips to Medicare beneficiaries under the DMEPOS benefit, you must have a complete Proof of Refill Request and Proof of Delivery as per June 2021 Newsline, DMEPOS Proof of Delivery and Refill Request Requirements
- February 2020 – Self-Audit Series #13: Diabetic Test Strips
- March 2020 – Self-Audit Series #14: DMEPOS Items
- April 2021 – Are You Overbilling on Test Strips?
- July 2021 – LifeScan Hires Law Firm to Pursue Pharmacies Purchasing from Unauthorized Distributers
- January 2022 – Common Claim Denials for Medicare Part B
- New Tool on PAAS Portal – Exceeding Days’ Supply Plan Limits for Unbreakable Packages - December 1, 2024
- Understanding Biologic Substitutions – New Tool Available! - November 12, 2024
- FDA Proposed Guidance for Biosimilar Updates - October 23, 2024